Fda advisory committee votes in favor of abbott's first-of-its-kind triclip™ system to treat people with a leaky tricuspid heart valve

Panel of independent experts reviewed data from the triluminate™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the triclip system an investigational device in the u.s., triclip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide abbott park, ill., feb. 13, 2024 /prnewswire/ -- abbott (nyse: abt) today announced that the circulatory system devices panel of the medical devices advisory committee for the u.s. food and drug administration (fda) confirmed 13 to 1, with 0 abstention that the benefits of abbott's triclip™ transcatheter edge-to-edge repair (teer) system outweighed the risks for the treatment of people with tricuspid regurgitation (tr).
ABT Ratings Summary
ABT Quant Ranking